Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy (CS)
Breast Neoplasms, Treatment, Metastatic Breast Cancer
About this trial
This is an interventional treatment trial for Breast Neoplasms focused on measuring Breast Neoplasms, de-novo metastatic breast cancer, surgical treatment
Eligibility Criteria
Study Population Operable stage IV breast cancer patients, whose primary lesion is invasive breast cancer confirmed by pathology, and metastases can be confirmed by pathology or imaginology examination
Inclusion Criteria:
- Operable stage IV breast cancer patients,whose primary lesion is invasive breast cancer confirmed by pathology, and metastases can be confirmed by pathology or imageology examination.
- ECOG-PS 0-2.
- Bone marrow, liver and kidney should be fully functional.
- Patients didn't received the locoregional surgery of the primary tumor in de novo.
- For the patient who accepted systematic treatment before operation, the systematic treatment must be administered within a year since diagnosed.
Exclusion Criteria:
- Accompanied with other primary malignant tumors.
- More than two visceral organ involvement.
- Patients who can't plan for follow-up effectively and regularly.
- Multiple liver metastases with deranged liver function tests (SGOT/SGPT more than four times the upper normal limit).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
1 Primary and metastatic lesions PCR
2 Primary lesions NPCR and metastatic lesions PCR
3 Primary lesions PCR and metastatic lesions NPCR
4 Primary lesions NPCR and metastatic lesions NPCR
surgery 1 Mastectomy OR Breast conserving surgery
surgery 1 Mastectomy OR Breast conserving surgery
surgery 2 Resection of metastasis
Systemic therapy Endocrine therapy or chemotherapy or targeted therapy